Journal
DRUG TESTING AND ANALYSIS
Volume 10, Issue 3, Pages 592-596Publisher
WILEY
DOI: 10.1002/dta.2250
Keywords
adalimumab; Crohn's disease; optical biosensor; surface plasmon resonance; therapeutic drug monitoring
Funding
- Fonds Wetenschappelijk Onderzoek (FWO, Flanders) [G.0617.12]
- KU Leuven [IOF/KP/12/002, C22/15/025]
Ask authors/readers for more resources
Therapeutic drug monitoring of adalimumab is recommended to improve therapeutic outcome in patients with Crohn's disease. Performing an ELISA requires a rather long time-to-result and the necessity of collecting multiple samples to decrease the cost per adalimumab determination. In this study, we aim to develop and validate a rapid assay suitable for measuring a single adalimumab serum sample using a fiber-optic surface plasmon resonance (FO-SPR) based sensor. Therefore, we have immobilized MA-ADM28B8 as capture antibody on an FO-probe and conjugated MA-ADM40D8 as detecting antibody to gold nanoparticles. A dose-response curve ranging from 2.5 to 40ng/mL adalimumab was obtained in 1/400 diluted serum. Serum samples of patients with adalimumab concentrations between 1 and 16g/mL were measured whereas the negative control, a sample spiked with infliximab at a concentration of 16g/mL, showed no significant signal. Using a pre-functionalized FO-probe, the technology requires less than 45minutes for measuring a single sample. Comparison of measurements between the biosensor and the ELISA revealed an excellent agreement with a Pearson r coefficient of 0.99 and an intra-class coefficient of 0.99. The reduced assay time and the possibility of measuring a single sample are major advantages compared to the ELISA. The developed and validated optical adalimumab biosensor could be a valuable point-of-care diagnostic tool for adalimumab quantification in patients with Crohn's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available